| アブストラクト | AIM: The present study investigated the risk of bleeding when antidepressants are added to antithrombotics. METHODS: Using data registered in VigiBase((R)), the WHO pharmacovigilance database, between 01/01/2000 and 31/12/2022, we compared the risk of reporting "serious" bleeding (Reporting Odds Ratio, ROR) with antidepressants + antithrombotics versus antithrombotics alone. RESULTS: Increased values of ROR were found for the association Serotonin Reuptake Inhibitors (SRIs) + Direct Oral Anticoagulants (DOACs) versus DOACs alone (ROR=1.49(1.17-1.89)). Similar results were found for Factor Xa inhibitors or Thrombin inhibitors. This association was also found for other antithrombotics: Vitamin K Antagonists (ROR=1.37(1.12-1.68)), Platelet Aggregation Inhibitors PAIs (ROR=1.38(1.21-1.57)) and Heparins (2.04(1.59-2.62)) but not with other antidepressants (Non-Selective Monoamine Reuptake Inhibitors, NSMRIs). CONCLUSION: The present study suggests an increased risk of "serious" bleeding when SRIs (but not NSMRIs) are associated with antithrombotics (all antithrombotics and not only DOACs). |
|---|
| ジャーナル名 | European journal of clinical pharmacology |
|---|
| Pubmed追加日 | 2023/12/19 |
|---|
| 投稿者 | Montastruc, Jean-Louis; Bura-Riviere, Alessandra |
|---|
| 組織名 | Clinical Pharmacologist, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.;Department of Vascular Medicine, Toulouse University Hospital, Toulouse, France.;Department of Medicine, University of Health, Toulouse, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38112734/ |
|---|
